# Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)

> **NCT02054351** · PHASE1 · COMPLETED · sponsor: **Ganymed Pharmaceuticals GmbH** · enrollment: 42 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** IMAB027

## Key facts

- **NCT ID:** NCT02054351
- **Lead sponsor:** Ganymed Pharmaceuticals GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-06
- **Primary completion:** 2015-10-28
- **Final completion:** 2015-10-28
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2024-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02054351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02054351, "Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02054351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*